Regenxbio
Open
$6.65
Prev. Close
$6.65
High
$6.67
Low
$6.62
Market Snapshot
$343.74M
-1.2
-4.60
$83.33M
371
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The company is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company is headquartered in Rockville, Maryland and currently employs 371 full-time employees. The company went IPO on 2015-09-17. The firm has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address an array of diseases. The company is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. The company is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. The company is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The company is developing RGX-121 for the treatment of Mucopolysaccharidosis type II (MPS II), and RGX-111 to treat Mucopolysaccharidosis Type I.
Recently from Cashu
Regenxbio Advances Gene Therapy RGX-202 for Duchenne Muscular Dystrophy in Promising Phase III Trial
REGENXBIO Inc. (Ticker: RGNX) has made significant strides in the development of its gene therapy RGX-202 for Duchenne Muscular Dystrophy (DMD), as demonstrated by the recent results from its pivotal…
REGENXBIO to Showcase Gene Therapy Advances at 2026 ASGCT Annual Meeting in Boston
REGENXBIO Inc. is set to highlight its advancements in gene therapy at the upcoming 2026 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place from May 11-15 in Boston, Massachu…
Legal Action Against REGENXBIO's Dr. Pakola Highlights Gene Therapy Safety Concerns
Dr. Pakola's Legal Woes Spotlight Safety Concerns in Gene Therapy Dr. Stephen Pakola, M.D., currently serving as the Executive Vice President and Chief Medical Officer at REGENXBIO, faces a securities…
Regenxbio Faces Class Action Lawsuits Over Misleading Claims on RGX-111 Gene Therapy
Legal Challenges Loom for Regenxbio Over RGX-111 Assertions Regenxbio Inc., a biotechnology company specializing in gene therapy, faces significant legal challenges stemming from class action lawsuits…